Cargando…

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Carcinoembryonic antigen (CEA) is the most widely used tumor marker in metastatic colorectal cancer (mCRC). However, its potential as a predictive marker of progression in mCRC during systemic chemotherapy, particularly in patients receiving monoclonal antibodies as a combination therapy, has remain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Sora, Kim, Sun Young, Hong, Yong Sang, Kim, Tae Won, Choi, Ki Eun, Kim, Min Jung, Kim, Jeong Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130020/ https://www.ncbi.nlm.nih.gov/pubmed/37185297 http://dx.doi.org/10.1038/s41598-023-33811-x

Ejemplares similares

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Epitopes of carcinoembryonic antigen (CEA) defined by monoclonal antibodies.
por: Price, M. R.
Publicado: (1988)

Autoradiographic Analysis of Radiolabeled Anti‐carcinoembryonic Antigen Monoclonal Antibody CEA102 in Colorectal Cancer Using Computed Radiography
por: Satoh, Tsuyoshi, et al.
Publicado: (1992)

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
por: Yuan, Zi-Xu, et al.
Publicado: (2013)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies
por: Kim, Ki Yeon, et al.
Publicado: (2019)

Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer
por: Dho, So Hee, et al.
Publicado: (2018)

Carcinoembryonic antigen (CEA) expression and heterogeneity in primary and autologous metastatic gastric tumours demonstrated by a monoclonal antibody.
por: Hockey, M. S., et al.
Publicado: (1984)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

Application of monoclonal antibodies to purified CEA in clinical radioimmunoassay of human serum.
por: Rogers, G. T., et al.
Publicado: (1981)

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
por: Mao, C, et al.
Publicado: (2010)

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line
por: Fiala, Ondrej, et al.
Publicado: (2018)

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
por: Shinozaki, Eiji, et al.
Publicado: (2017)

Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer.
por: Blair, S. D., et al.
Publicado: (1990)

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy
por: Kim, Jeong Eun, et al.
Publicado: (2022)

The site of binding of anti-CEA antibodies to tumour CEA in vivo: an immunocytochemical and autoradiographic approach.
por: Moshakis, V., et al.
Publicado: (1982)

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
por: Dankner, Matthew, et al.
Publicado: (2018)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
por: Hsieh, Meng-Chiao, et al.
Publicado: (2018)

Localisation of gastrointestinal cancer with a 131 I labelled monoclonal antibody to CEA.
por: Allum, W. H., et al.
Publicado: (1986)

Thermo-stability and antitumor activity on colon cancer cell lines of monoclonal anti-CEA antibody-saporin immunotoxin.
por: Manosroi, J., et al.
Publicado: (1992)

Imaging of Recurrent Intestinal Carcinoma with Indium‐lll‐labeled Anti‐carcinoembryonic Antigen Monoclonal Antibody CEA102
por: Nakada, Kazuhiko, et al.
Publicado: (1997)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
por: Shinozaki, Eiji, et al.
Publicado: (2018)

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies
por: Popa, C, et al.
Publicado: (2012)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Lu, Xiaona, et al.
Publicado: (2023)

Syndecan-1 Expression Is Associated with Tumor Size and EGFR Expression in Colorectal Carcinoma: A Clinicopathological Study of 230 Cases
por: Kim, Su Young, et al.
Publicado: (2015)

Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels
por: Kim, Jeong Yeon, et al.
Publicado: (2009)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_8fie2ic1eg486bkjun8t2v11n7